지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.9
- 수록면
- 163 - 168 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Titanium silicate (TS)-1 chemotherapy has been widely used against gastric cancer in Japan. The aim of the present study was to assess the efficacy and hematological safety of TS-1 as treatment for advanced and recurrent gastric cancer. Methods: From September 2006 to February 2011, 51 advanced or recurrent gastric cancers were treated with TS-1. One course of treatment consisted of 40, 50, or 60 mg/m<sub>2</sub> of TS-1 twice a day for 28 days, followed by withdrawal for two weeks. The primary end point was progression-free survival (PFS), and the secondary end point was overall survival (OS). Results: The disease control rate was 39.2% (complete response, 0/51; partial response, 6/51; stable disease, 14/51; progressive disease, 23/51; not evaluable, 8/51). The median PFS was 4.0 months (95% confidence interval [CI], 2.2 to 5.7); the median PFS of the advanced group was 6.0 months (95% CI, 2.8 to 9.1), and the median PFS of the recurrent group was 3.0 months (95% CI, 1.8 to 4.1). The median OS was 11.0 months (95% CI, 6.3 to 15.6); the median OS of the advanced group was 10.0 months (95% CI, 4.9 to 15.0), and the median OS of the recurrent group was 14.0 months (95% CI, 4.1 to 23.8). Grade 3 or 4 hematological toxicity occurred in three patients (5.9%), anemia occurred in two patients (3.9%), and thrombocytopenia occurred in one patient (2%). Conclusion: TS-1 chemotherapy was safe and effective, with relatively long PFS and OS in patients with advanced and recurrent gastric cancers.
목차
Purpose
INTRODUCTION
METHODS
RESULTS
DISCUSSION
CONFLICTES OF INTEREST
REFERENCES
참고문헌 (27)
참고문헌 신청
1. [학술지(정기간행물)] - Roukos DH / 2000 / Current status and future perspectives in gastric cancer management / Cancer Treat Rev 26 : 243 ~ 255
2. [학술지(정기간행물)] - Sakata Y / 1998 / Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients / Eur J Cancer 34 : 1715 ~ 1720
3. [학술지(정기간행물)] - Koizumi W / 2000 / Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group / Oncology 568 : 191 ~ 197
4. [학술지(정기간행물)] - Shirasaka T / 1996 / Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats / Cancer Res 56 : 2602 ~ 2606
5. [학술지(정기간행물)] - Kondo K / 1996 / Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer / Oncology 53 : 64 ~ 67
2. [학술지(정기간행물)] - Sakata Y / 1998 / Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients / Eur J Cancer 34 : 1715 ~ 1720
3. [학술지(정기간행물)] - Koizumi W / 2000 / Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group / Oncology 568 : 191 ~ 197
4. [학술지(정기간행물)] - Shirasaka T / 1996 / Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats / Cancer Res 56 : 2602 ~ 2606
5. [학술지(정기간행물)] - Kondo K / 1996 / Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer / Oncology 53 : 64 ~ 67
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-002683810